Ron Leyland serves as President and CEO of Puget Technologies, the publicly-traded parent company of Cannabis Biotech. He is responsible for guiding the company’s overall direction, implementing their mission and vision. Further, Leyland is in charge of developing strategic opportunities to increase share-holder value.
Before his time with Puget Technology, Leyland founded Nexagen USA in 2002. Leveraging the company’s successful launch of its initial proprietary product, the Jen Fe Diet Patch, he assembled an expert research and development team. They went on to develop a well-accepted product line consisting of patches, pills, lotions and drinks utilizing multiple delivery systems. Leyland later expanded his brand with the launch of NexEurope.
In addition to his work with Nexagen, Leyland has created successful corporations to conduct neutraceutical research and development and to provide credit card payment solutions. He founded USA Cellular, LLC. as well.
Based in Fort Lauderdale, Florida, Cannabis Biotech is a subsidiary of Puget Technologies (OTC: PUGE). The publicly held company is led by President and CEO Ron Leyland. Cannabis Biotech conducts research to develop innovative cannabinoid products and therapies for the treatment of diseases and their symptoms. Ailments that the company has studied include HIV, cancer, glaucoma and neurological disorders. Thus far, Cannabis Biotech has developed a number of products that utilize alternative delivery methods. For instance, they have developed nasal spray and trans-dermal skin patches geared towards treatment via cannabinoids. Further, they are developing cannabis infused beverages that utilize natural …
DISCLAIMER: The professionals and companies described are not associated or affiliated with Medical Jane, and they
may not endorse Medical Jane or the information provided. The names of other companies, products and services are
the property of their respective owners.